ArriVent's Firmonertinib Shows 68% Response Rate at 240 mg in Phase 1b Lung Cancer Trial

• ArriVent Biopharma announced publication in Cancer Cell of Phase 1b firmonertinib results in previously untreated, advanced EGFR PACC-mutant non-small cell lung cancer.
• Results showed durable tumor responses, including activity against brain metastases, with a manageable safety profile consistent with prior studies.
• The findings support the ongoing global Phase 3 ALPACCA trial comparing firmonertinib with osimertinib or afatinib as first-line treatment.
• The targeted patient population currently has no established targeted standard of care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190801PRIMZONEFULLFEED9847798) on October 19, 2026, and is solely responsible for the information contained therein.